T his edition of Society Updates is typically devoted to the program outline for the annual SBS Conference & Exhibition, which will be held in Geneva, Switzerland, September 10 to 15, 2005 . A condensed version of the final program appears at the end of this section, but for full details, visit www.sbsonline.org. A special thank you goes to our Platinum Sponsor, Meso Scale Discovery, and our Bronze Sponsors-ASDI, Biacore, Cisbio International, and GE Healthcare-which help support the Society and add value to the conference program.
In addition, a brief report on the San Francisco Regional Meeting follows, and a copy of the annual audit, conducted by BlumShapiro & Company, PC, Certified Public Accountants, appears on the pages immediately following the Society Updates section. Financially, 2004 ended on a positive note for the Society for Biomolecular Screening (SBS). This was in spite of several challenges, including a lackluster economy and a stagnant jobless rate. The Society also found itself facing the worst hurricane season in years, which raised concern over the success of the 10th annual conference and anniversary celebration. Despite all of these potential obstacles, the net profit at year-end reached $97,987, exceeding the approved budget by 18.7%. Reserves increased from 85% at the start of 2004 to 85.92% at year-end, which is within the acceptable range (75%-125% of operating cash) set by the board.
A brief word about cash reserves: all associations wish to have cash reserves on hand, but there is no standard agreement as to how large the reserves should be. Reserves enable an organization to weather a storm, such as hard economic times, tenuous financial returns on programs, and unprofitable policy decisions regarding programming-all of which can happen regardless of best efforts to head them off. Reserves also allow the organization to take advantage of opportunities that arise, such as purchasing new equipment, launching new programs, and conducting research, to name a few. Finally, reserves also provide ongoing nondues investment income that helps reduce dependency on dues and helps keep dues increases modest. A case in point: SBS managed to postpone its first dues increase until 2004. As we enter our 11th year, SBS is still a relatively young organization with significant opportunities for growth in programs and services. The cash reserves will provide a safety net as we continue to evolve.
SBS SAN FRANCISCO REGIONAL MEETING REPORT-"EXPLOITING THE DRUGGABLE GENOME: A WEST COAST FOCUS"
Richard M. Eglen, Mike Biros, and John Wang
On April 21 to 22, 2005, SBS held a regional meeting in the San Francisco Bay Area. SBS wishes to thank the program organizers for putting together an excellent program with expert speakers coming from West Coast pharmaceutical, biotechnological, and academic institutions. The conference was well attended, with more than 230 registrants, numerous posters, and extensive representation from more than 30 vendors.
The following is a brief report on the meeting by 3 members of the local organizing committee. In full, this comprised R. Eglen (DiscoveRx, program chair), M. Biros (consultant), and J. Wang (Chiron), accompanied by H. Bullock and K. Tynan in the early planning meetings. J. Concepcion coordinated the exhibition portion of the conference, and meeting planning and logistics were handled by A. Cox (SBS).
Genomic Medicine
R. Booth (Celera Genomics) opened the meeting with the conference plenary talk titled "The Future of Genomic Medicine." This presentation provided a perspective on the use of genomics and proteomics in drug discovery and therapeutic intervention. Dr. Booth emphasized the integration of genomics and diagnostics in improved design of therapeutics and prediction of clinical efficacies (i.e., targeted medicine). He then described a large-scale analysis of mutations in rheumatoid arthritis, focusing on the disease association of the R622W allelic form of PTPN22. The protein possesses a single-nucleotide polymorphism (SNP) present in 28% of rheumatoid arthritis patients, conferring a 2-fold increased risk factor. The role of the SNP in altering TGFβ signaling, particularly at the level of the enzyme csk, was highlighted, as was its potential causal role in other autoimmune diseases. Dr. Booth also described the importance of patient profiling in the identification of kinase inhibitors because it is now evident that kinase mutations markedly influence the clinical efficacy of epidermal growth factor receptor (EGFR) inhibitors such as Iressa. In closing, the importance of patient stratification was stressed, as well as the identification of biomarkers early in a drug discovery program. Here, both activities require the full integration of genomic and proteomic technologies in preclinical and clinical areas.
Target-Based Drug Discovery
A. Harris (Chiron Corp.) extended the theme of optimizing preclinical studies, specifically with respect to the design of novel kinase therapeutics. He stressed integration of several approaches by describing the relationship between a target and therapeutic area focus at Chiron. He then moved to a discussion of CHIR-258, a novel treatment approach for several cancers. CHIR-258 is a multitargeted kinase inhibitor, acting at class III, IV, and V tyrosine kinases. It inhibits angiogenesis in several preclinical models and appears to be more efficacious than a selective vascular endothelial growth factor (VEGF) inhibitor. Dr. Harris concluded by highlighting the importance of "translational medicine" efforts (i.e., those functions that bridge the gap between research and development in development compounds such as CHIR-258).
J. Tsai (Plexxikon, Inc.) discussed kinase inhibitor programs from the perspective of rational drug design, specifically by using critical chemical scaffolds coupled to information derived from co-crystallography studies. These techniques resulted in the use of smaller and more focused libraries in drug discovery programs, one of which was exemplified by the B-RafV99E inhibitor program. Here, more than 200 broadly active scaffolds were identified and analyzed using co-crystallization studies, resulting in 50 leads for subsequent chemical optimization. These included PLX3204 and PLX3331, the latter being a potent inhibitor now under clinical evaluation for the treatment of A375 melanomas.
In the ion channel area, J. McGivern (Amgen, Inc.) discussed the rationale and progress in identifying a selective T-calcium channel inhibitor for use in neuropathic pain. The use of highthroughput systems to identify compounds blocking Ca v 3 channels was described, including an in-house system for lead optimization that employs aequorin Flash luminometry. However, the importance of electrophysiology, particularly automated patch clamp analysis systems, was stressed because of the large number of false positives emanating from the cell-based screens. The need to define mode of action of both novel and existing agents was also addressed.
There were 2 talks in the G protein-coupled receptor area. The first was by M. Morton (J&J PRD), who reviewed a drug discovery program aimed at identifying CCK-2 receptor antagonists. The high-throughput screening (HTS) strategy involves using technology pioneered by Sangamo Biosciences, which uses engineered transcription factors to upregulate target proteins in endogenous cell lines. This expression system was validated using a selection of known reference antagonists and compared to traditional recombinant methods. The lead compound was then characterized using a hierarchy of functional assays increasing in complexity. The lead J&J PRD compound was shown to be a potent, selective CCK-2 receptor antagonist with good pharmacokinetic properties.
B. Koch (Roche Bioscience) described how the adoption of various screening technologies to study agonists and antagonists of G protein-coupled receptors is used at Roche. These techniques included accumulation assays for calcium mobilization, the use of the fluorescent imaging plate reader (FLIPR) instrumentation and cyclic adenosine monophosphate (cAMP), and the use of enzyme fragment complementation. Additional screens were also undertaken using GFP-β arrestin redistribution as a marker for guanine protein-coupled receptor (GPCR) activation, analyzed by highthroughput confocal imaging systems.
J. Finer (Cytokinetics, Inc.) reviewed approaches to various cytoskeletal drug discovery proteins that used multiprotein bio-chemical screens to recapitulate cellular protein interactions. Lead compounds were identified and then prioritized using several automated image-based cell assays. These techniques were also used throughout the hit and lead optimization phases of discovery, thereby accelerating the identification of drug candidates. These included compounds suitable as mitotic kinesin inhibitors, novel cancer agents, cardiac myosin activators, novel agents for congestive heart failure, and compounds influencing actin cytoskeletal dynamics as potential approaches to the treatment of inflammatory diseases.
H. Lowman (Genentech, Inc.) described the use of engineered antibodies as alternatives to small-molecule therapeutics in drug discovery. These are used to block the action of CD40, a protein found on B cells that is targeted by drugs such as Rituxan to treat non-Hodgkin lymphoma. The goal in this program was to identify humanized anti-CD20 antibodies for use in the disease, acting to induce B cell depletion. Currently, more than 100 humanized variants have been investigated in primates or transgenic mice, and a series with Fc variants of v16 (such as v31) now shows enhanced activity.
Biomarkers in Drug Discovery
Biomarkers act as indicators of a phenotypically altered state and may be used to detect different disease states, track severity of disease, or monitor response to drug treatments. The area of biomarkers in drug discovery and clinical validation was discussed by 2 speakers, the first of whom was L. Lomas (Ciphergen Biosystems, Inc.). When designing a novel biomarker assay, a pilot study is undertaken to identify multiple biomarker candidates. These biomarkers are then validated against a larger sample set, and only those markers that provide high sensitivity and specificity are developed further. Two examples were given to exemplify the application of biomarkers to "translational medicine." The first described the use of biomarkers in predictive preclinical toxicology studies, in which several biomarkers were identified emanating from specific drug treatments. Indeed, approximately 44% of these biomarkers were validated, and these were then purified for full characterization. A second use involved biomarkers that allow for the study of drug efficacy in preclinical models. Here, 3 marker proteins were identified, purified, and developed to monitor drug efficacy for compound identification.
A. Kantor (SurroMed, Inc.) also discussed the use of biomarkers, emphasizing that they can vary between human and animals as well as between in vivo and in vitro studies. A key bioanalytical technology platform is employed using a combination of capillary cell electrophoresis coupled to liquid chromatography/ mass spectrometry (LC/MS) detection. Many programs use phenotypic biomarkers, including metabolites, carbohydrates, protein-protein interactions, mRNA/DNA levels, and cell typing. The assays in place at Surromed possess high precision and produce data that concur well with those detected by enzyme-linked immunosorbent assay (ELISA) methods. Currently, immuno-
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phenotyping has resulted in the identification of approximately 700 markers.
Academic Screening
The meeting was well represented by 3 speakers from the academic community, each of whom described various approaches to the implementation of HTS techniques. J. Inglese (NIH Chemical Genomics Center) presented a keynote talk on 1 outcome of the National Institutes of Health (NIH) roadmap initiatives, namely, the establishment of the Chemical Genomics Center. The aim of the center is to identify small-molecule leads for use by the research community as probes that perturb cellular function, probes for imaging, or as leads for novel therapeutics. The convergence of new technologies providing for novel compound libraries, assay techniques, and genome-derived data has resulted in a national Molecular Libraries Screening Center Network. In contrast to the types of targets entering pharma or biotech screening groups, many of the targets under consideration in the Network fall outside of those generally considered for drug discovery. A 2nd difference is that the resulting data will be publicly available in PubChem. As mentioned by Dr. Inglese, the overall goal is to bring technological advances primarily practiced in the private sector to academic scientists.
D. Solow-Cordero (Stanford University) reviewed the screening work undertaken at the High-Throughput Bioscience Center (HTBC) at Stanford University School of Medicine. This facility provides researchers with the ability to obtain data from highthroughput chemical, cDNA, siRNA, and high-content screens across several targets and assays. Dr. Solow-Cordero emphasized the use of defined and agreed "acceptance criteria" to transfer assays into the group for screening. One example of a recent screen conducted in the group used renal cell carcinoma (RCC) cell lines matched for Von Hippel Landau (VHL) expression (VHL deficient and VHL positive).
R. Kip Guy (UCSF) described various strategies for the identification of compounds for the treatment of malaria, a disease growing in prevalence because of a rise in resistance to current chloroquinone therapy. Prof. Guy addressed the use of phylogenomic profiling, in which clustering analyses allow identification of key genes involved in species-specific pathways. This permits identification of targets either nonessential or nonexistent in humans, such as type II fatty acid biosynthesis. Diarylurea scaffolds were identified that selectively interact at this pathway in the disease vector, the Anopheles mosquito. An alternative approach exploits differences in compound metabolism, resulting in the identification of compounds using structural homology. By molecular profiling strategies, a series of compounds was identified that could be developed for later medicinal chemistry optimization.
Summary
Collectively, this SBS regional meeting provided a highly interactive venue for drug discovery groups to discuss various applications of genomic and proteomic data, either as novel targets or biomarkers, as well as the subsequent development of small molecules and biotherapeutics as therapeutics. This meeting was the second such SBS regional meeting held on the West Coast, the first being convened in 2001. The growth in size and attendance of the 2nd meeting over the first attested to the regional interest in the SBS and the vigorous way in which the West Coast community is indeed "exploiting the druggable genome."
Respectfully submitted,
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